NDAINJECTIONINJECTABLE
Approved
Sep 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIMETANE-TEN is an injectable formulation of brompheniramine maleate, a first-generation H1-receptor antagonist (antihistamine) approved in 1958 for parenteral use. It treats acute allergic reactions and urticaria when oral administration is not feasible, working by competitively blocking histamine at H1 receptors. This legacy injectable antihistamine represents a foundational therapeutic category now dominated by newer agents and alternative routes.
LOE Approaching
Approaching loss of exclusivity with minimal commercial investment and likely contracting market presence suggests a small, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents
Started Mar 2009
37 enrolled
Allergic Reactions
Career Relevance
Working on DIMETANE-TEN offers limited career advancement given the product's LOE-approaching status and zero linked job openings; this is a defensive, cost-optimization role rather than a growth opportunity. Best suited for professionals seeking stability in a mature product portfolio or transition into supply-chain and manufacturing optimization.
Brand Manager (legacy portfolio)
Worked on DIMETANE-TEN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.